GW Pharmaceuticals has appointed Darren Cline as its new U.S. chief commercial officer. Darren will lead the Epidiolex U.S. commercial organisation and is expected to start on April 22, 2019.
He is an accomplished biopharmaceutical executive with over 25 years of commercial experience and was previously executive Vice president, commercial and a member of the executive committee at Seattle Genetics, where he oversaw all marketing, sales, and managed markets functions.
“I am very excited to join GW and to lead such a talented U.S. commercial team,” said Cline. “Epidiolex is an important new treatment that offers hope to many patients with Lennox-Gastaut Syndrome and Dravet syndrome who are in desperate need of new treatments to reduce their seizures. I look forward to continuing to deliver on GW’s mission of bringing transformational medicines to patients and building on the successful commercial organization in place to maximize the Epidiolex opportunity.”
He also held commercial leadership positions at Intermune and Amgen, and received his undergraduate degree from San Diego State University and his MBA from Pepperdine University.
